fampridine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4163	504-24-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fampyra dalfampridine ampyra pyridin-4-amine 4-aminopyridine fampridine	One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. Molecular weight: 94.12 Formula: C5H6N2 CLOGP: 0.32 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 38.91 ALOGS: 0.46 ROTB: 0

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fampyra
dalfampridine
ampyra
pyridin-4-amine
4-aminopyridine
fampridine

One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.

Molecular weight: 94.12
Formula: C5H6N2
CLOGP: 0.32
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 38.91
ALOGS: 0.46
ROTB: 0

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	90.30 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	9.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	112 mg/mL	Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 22, 2010	FDA	ACORDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1963.23	14.64	831	38658	47647	63401886
Urinary tract infection	1451.44	14.64	1244	38245	263440	63186093
Laboratory test abnormal	1010.84	14.64	438	39051	26474	63423059
Balance disorder	767.03	14.64	537	38952	83885	63365648
Multiple sclerosis	730.90	14.64	339	39150	24033	63425500
Fall	706.66	14.64	1031	38458	391303	63058230
Gait disturbance	617.11	14.64	660	38829	182518	63267015
Urine analysis abnormal	598.43	14.64	191	39298	4825	63444708
Therapy cessation	502.05	14.64	283	39206	30174	63419359
Muscular weakness	408.10	14.64	439	39050	121914	63327619

Showing 1 to 10 of 260 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	1000.45	20.70	318	13452	12815	34930346
Multiple sclerosis	464.73	20.70	151	13619	6494	34936667
Balance disorder	332.41	20.70	204	13566	40450	34902711
Gait disturbance	307.90	20.70	260	13510	84880	34858281
Laboratory test abnormal	300.78	20.70	151	13619	20240	34922921
Urinary tract infection	296.30	20.70	253	13517	83828	34859333
Fall	287.84	20.70	375	13395	202510	34740651
Muscle spasticity	275.29	20.70	99	13671	5789	34937372
Drug ineffective	179.31	20.70	485	13285	456266	34486895
Relapsing-remitting multiple sclerosis	166.51	20.70	45	13725	1005	34942156

Showing 1 to 10 of 90 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	2224.08	14.69	842	38428	45691	79659427
Urinary tract infection	1710.91	14.69	1263	38007	273249	79431869
Laboratory test abnormal	1616.92	14.69	583	38687	27465	79677653
Multiple sclerosis	737.87	14.69	310	38960	21972	79683146
Fall	710.62	14.69	1025	38245	486604	79218514
Balance disorder	674.14	14.69	482	38788	98375	79606743
Urine analysis abnormal	642.50	14.69	203	39067	6317	79698801
Gait disturbance	472.02	14.69	545	38725	206961	79498157
Muscular weakness	344.92	14.69	410	38860	160319	79544799
Muscle spasticity	343.98	14.69	181	39089	21294	79683824

Showing 1 to 10 of 293 entries

Previous1 2 3 4 5…30Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N07XX07	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs
CHEBI has role	CHEBI:33289	avicides
CHEBI has role	CHEBI:71031	orphan drugs
FDA EPC	N0000192795	Potassium Channel Blocker
FDA MoA	N0000175448	Potassium Channel Antagonists
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D026902	Potassium Channel Blockers

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Multiple sclerosis	indication	24700007	DOID:2377
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003

Showing 1 to 3 of 3 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.58	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-gated potassium channel	Ion channel	O43525 O43526 O95259 P16389 P17658 P22001 P22459 P22460 P48547 P51787 P56696 Q03721 Q09470 Q12809 Q14003 Q14721 Q16322 Q6PIU1 Q8NCM2 Q8TAE7 Q8TDN1 Q8TDN2 Q92953 Q96KK3 Q96L42 Q96PR1 Q96RP8 Q9BQ31 Q9H252 Q9H3M0 Q9NR82 Q9NS40 Q9NSA2 Q9NZV8 Q9UIX4 Q9UJ96 Q9UK17 Q9ULD8 Q9ULS6 Q9UQ05	KCNQ3_HUMAN KCNQ2_HUMAN KCNH1_HUMAN KCNA2_HUMAN KCNA6_HUMAN KCNA3_HUMAN KCNA4_HUMAN KCNA5_HUMAN KCNC1_HUMAN KCNQ1_HUMAN KCNQ4_HUMAN KCNC4_HUMAN KCNA1_HUMAN KCNH2_HUMAN KCNC3_HUMAN KCNB1_HUMAN KCA10_HUMAN KCNV1_HUMAN KCNH5_HUMAN KCNG3_HUMAN KCNG4_HUMAN KCNV2_HUMAN KCNB2_HUMAN KCNS1_HUMAN KCNH8_HUMAN KCNC2_HUMAN KCNA7_HUMAN KCNS3_HUMAN KCNH6_HUMAN KCNF1_HUMAN KCNQ5_HUMAN KCNH7_HUMAN KCND1_HUMAN KCND2_HUMAN KCNG1_HUMAN KCNG2_HUMAN KCND3_HUMAN KCNH3_HUMAN KCNS2_HUMAN KCNH4_HUMAN	BLOCKER	IC50	4.05	CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily C member 1	Ion channel		KCNC1_MOUSE	BLOCKER	IC50	4.50	IUPHAR
Potassium voltage-gated channel subfamily C member 2	Ion channel		KCNC2_RAT	BLOCKER	IC50	4.60	IUPHAR

Showing 1 to 3 of 3 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
4AP	PDB_CHEM_ID
006829	NDDF
170373	MMSL
1727	PUBCHEM_CID
2416	IUPHAR_LIGAND_ID
26967	MMSL
4025700	VANDF
4025705	VANDF
4029704	VUID
4029704	VANDF

Showing 1 to 10 of 24 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
AMPYRA	HUMAN PRESCRIPTION DRUG LABEL	1	10144-427	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0479	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0509	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	NDA authorized generic	27 sections
dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4504	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2533	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	27 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
Dalfampridine	HUMAN PRESCRIPTION DRUG LABEL	1	16729-292	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	29 sections
DALFAMPRIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-275	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections

Showing 1 to 10 of 21 entries

Previous1 2 3Next